BRIEF COMMUNICATION
Cellular and Molecular Biology

Platelets enhance malignant behaviours of gastric cancer cells via direct contacts

Ryo Saito1, Katsutoshi Shoda1, Suguru Maruyama1, Atsushi Yamamoto1, Koichi Takiguchi1, Shinji Furuya1, Naohiro Hosomura1, Hidenori Akaike1, Yoshihiko Kawaguchi1, Hitotake Amemiya1, Hiromichi Kawaida1, Makoto Sudo1, Shingo Inoue1, Hiroshi Kono1, Katsue Suzuki-Inoue2 and Daisuke Ichikawa

In this study, we aimed to analyse human cancer cell–platelet interactions in functional cell analyses and explore the molecular mechanisms behind tumour progression. Various functional analyses of gastric cancer (GC) cells were performed after direct/indirect co-incubation with platelets derived from GC patients. Further detailed expression and signalling analyses were performed after co-culture with direct and indirect GC cells–platelet contact. Malignant behaviours of cancer cells, such as proliferation, migration, invasion and adhesion, were significantly enhanced after direct co-incubation with platelets. Microarray analyses demonstrated changes in multiple genes, including epithelial–mesenchymal transition (EMT)-related genes. Among them, matrix metalloproteinase 9 was notably upregulated, which was validated by quantitative reverse transcription–polymerase chain reaction and western blot. Further, this change was only observed after direct co-incubation with platelets. This study demonstrated that platelets from GC patients promote malignant behaviours of GC cells through EMT-related signalling, especially by direct contact with tumour cells.

British Journal of Cancer (2021) 124:570–573; https://doi.org/10.1038/s41416-020-01134-7

BACKGROUND

Recent studies have elucidated that interactions of tumour cells with the surrounding tissues play pivotal roles in tumour invasion and progression.1 Other than cancer-associated fibroblasts, immune cells, one of blood cells, are also considered to be deeply involved in tumour progression.2,3 However, there are only a few studies about the interactions of cancer cells with platelets, even in the same blood cells. Although previous experiments using laboratory animals have demonstrated that platelets play various roles in cancer, including hematogenous metastasis, the detailed mechanisms by which platelets play pro-tumorigenic roles still remain unclear.4,5

Our previous clinical studies indicated that intraoperative haemorrhage is more likely to develop peritoneal recurrence.6 These findings prompted us to investigate the impact of platelets on tumour malignancy, especially concerning the development of peritoneal metastasis, by basic and clinical studies using human samples. In this study, we aimed to analyse human cancer cell–platelet interactions in functional cell analyses and explore the molecular mechanisms behind tumour progression.

METHODS

Human platelet samples and cell lines

Blood samples were collected from patients with advanced GC, before therapeutic interventions. Patient characteristics are shown in Supplementary Table 1. Platelets were purified from whole-blood samples. The human GC cell lines NUGC-3 and MKN74, and the human normal mesothelial cell line Met-5A, were used in analyses of cell functions and molecular mechanisms.

Observation of cancer cell–platelet complex and cell functional analyses

NUGC-3 co-cultured with platelets was observed by scanning electron microscopy (SEM). The functions of GC cells co-cultured with platelets were evaluated for proliferation, migration and invasion as well as adhesion abilities to mesothelial cells, each compared to those of GC cells not co-cultured with platelets. For comparison, these functional analyses were carried out in conditions of both direct and indirect contact between GC cells and platelets, using novel experimental systems (Supplementary Fig. 1).

Molecular mechanism analyses

Molecular analyses with a microarray were performed using NUGC-3 cells co-cultured with platelets for 48 h compared to those cultured without platelets as a control. Microarray analyses were also performed in GC cells co-cultured with platelets for 15 min and in GC cells co-cultured with platelets separated by 0.4-µm pore membranes. The former condition was helpful to eliminate the gene expression changes affected by intra-platelet mRNA, and the latter represented gene expression changes affected only by molecules and exosomes secreted by platelets (Supplementary Fig. 2).
Following microarray analysis, enrichment analyses of the altered mRNAs and functional pathways were performed using GO enrichment and KEGG pathway analysis, respectively. Then, validation analysis of the mRNA expression in each condition of cancer–platelet contact was performed using quantitative reverse transcription–polymerase chain reaction. Further, protein expression was also validated by western blotting. P < 0.05 was considered to indicate a statistically significant result in all analyses in this study. For detailed methods of each experiment, see Supplementary files.
RESULTS

Observation of electron microscopy and cell functional analyses

SEM imaging demonstrated that GC cells were surrounded by a number of platelets and adhered to the platelets in co-culture in as little as 15 min (Fig. 1a). The results of functional analyses are shown in Fig. 1b. The proliferation ability of GC cells was significantly enhanced by co-culture with platelets at all the time points evaluated (24 h and 48 h) in both GC cell lines, although the difference was more marked in NUGC-3 cells ($P < 0.001$, $P = 0.001$) than in MKN74 cells ($P = 0.014$, $P = 0.018$). The migration assay revealed that platelets significantly improved the migration abilities of both GC cell lines ($P < 0.001$ for both). Similarly, the invasion assay also revealed significantly more invasion after co-culture with platelets in both cell lines (NUGC-3, $P = 0.017$ and MKN74, $P = 0.002$). Adhesion assays using mesothelial Met-SA cells revealed that co-culture with platelets significantly increased the adhesion of GC cells (NUGC-3, $P = 0.036$ and MKN74, $P = 0.022$). Further, these enhanced malignant behaviours were observed after direct contact of GC cells with platelets, but not after indirect contact, in both NUGC-3 (Fig. 1c) and MKN74 (data not shown) cell lines.

Microarray and enrichment analyses

The microarray analyses identified 617 upregulated and 734 downregulated mRNAs with more than 1.5-fold differences in GC cells co-cultured with platelets for 48 h (Supplementary Table 2). The results of further GO and KEGG pathway analyses are shown in Supplementary Tables 3 and 4. The GO analysis indicated significant changes in genes involved in cell proliferation ($P < 0.001$), cell adhesion ($P = 0.003$) and cell migration ($P = 0.003$).

Next, alterations in genes related to the epithelial–mesenchymal transition (EMT), which is related to the migration and invasion abilities of cancer cells, were assessed (Supplementary Table 5). There were alterations in several EMT-related mRNAs in GC cells co-cultured with platelets, such as upregulation of matrix metalloenzyme 9 (MMP9) and integrin subunit alpha 5, and downregulation of claudin 1 and cadherin 1 (Supplementary Fig. 3). MMP9, which showed the most remarkable change in the microarray analyses, was used in further studies.

Validation in various contact models with platelets

The results of microarray analyses in various contact models clearly demonstrated that the MMP9 mRNA expression was extremely high only in direct contact for a 48-h model (Fig. 1d). Meanwhile, the MMP9 level was extremely low in both direct contact for 15 min and indirect contact for 48 h, indicating that the upregulation in MMP9 resulted from direct adhesion between GC cells and platelets. The results were also confirmed in validation experiments for mRNA expression in multiple samples (Fig. 1e), and for protein expression (Fig. 1f).

DISCUSSION

The results of this study clearly demonstrated that platelets enhanced several malignant behaviours of GC cells. The functional changes in migration and invasion were the most remarkable changes. All of these malignant changes have advantages for the development of peritoneal metastasis. Further detailed molecular analyses indicated that cancer cell–platelet interaction induced the expression of EMT-related genes in GC cells, and MMP9 was the most notably changed gene in the microarray analyses. One possible mechanism for these malignant changes is cellular stimulation by the adherence of platelets to cancer cells. The other is the influence of protein and exosomes secreted from platelets.7 Our further detailed co-culture analyses clearly demonstrated that enhanced malignant behaviours and significant elevation of MMP9 expression was observed only in conditions of direct cancer cell–platelet contact but not in transmembrane co-cultured condition. These results indicate that only direct adherence of platelets to cancer cells enhances malignant behaviour due to cancer cell–platelet interaction. Further, in these processes, platelet activation and production of platelet-derived soluble factors might be induced by direct contact with cancer cells.

Previous studies have reported that intraoperative blood loss (IBL) is correlated with prognosis in patients with GC who undergo surgery.8,9 Our previous analysis demonstrated that advanced GC patients who experience a large amount of IBL are more likely to develop peritoneal metastases.9 Kamei et al. also reported that large IBL during curative gastrectomy for advanced GC is associated with the development of peritoneal recurrence.10 These findings can potentially be explained by our current results. There were some limitations in this study, such as the small number of patients. Despite these limitations, our results have the absolute potential to lead to the establishment of a novel concept of cancer progression and metastasis and the development of treatments, based on cancer cell–platelet direct interactions.

In conclusion, this study obviously demonstrated that platelets from GC patients promoted malignant behaviour of GC cells through EMT-related manners, especially by direct contacts.

ACKNOWLEDGEMENTS

The authors are grateful to Ms. Arisa Oghara (University of Yamanashi, Yamanashi, Japan) for her expert technical assistance. The authors thank Dr. Issei Imoto (Aichi Cancer Research Institute, Nagoya, Japan) for his academic support.

AUTHOR CONTRIBUTIONS

R.S. performed the majority of the experiments and wrote the initial draft of the paper. D. I., K.S.-I., K.S. and S.M. designed the study and contributed to analysis and interpretation of data, and assisted in the preparation of the paper. A.Y. and K.T. assisted in experimental procedures. All authors (R.S., K.S., S.M., A.Y., K.T., S.F., N.H., Y.K., H.A., H. K., M.S., S.I., H.K., K.S.-I. and D.I.) have contributed to data collection and interpretation, and critically reviewed and approved the final version of the paper, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

ADDITIONAL INFORMATION

Ethics approval and consent to participate This study was approved by the Ethic committee of the University of Yamanashi (approved number 2159) and was performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. Written informed consent for the use of samples and clinical data was obtained from all patients.

Consent to publish Although detailed clinical data of patients were not included in this study, consents for publication were obtained from all of them included in this study.

Data availability The data sets used and analysed in this study are collected at the University of Yamanashi, and they are available from the corresponding author on reasonable request. Most of them are included in this paper.

Competing interests The authors declare no competing interests.

Funding information This study was performed mainly with expense grants of the University of Yamanashi, and partially supported by JSPS KAKENHI (17K10601 and 20K09031).

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-01134-7.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
REFERENCES

1. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
2. Ridge, S. M., Sullivan, F. J. & Glynn, S. A. Mesenchymal stem cells: key players in cancer progression. Mol. Cancer 16, 31 (2017).
3. Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G. & De Maria, R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol. Cancer 18, 70 (2019).
4. Xu, X. R., Yousef, G. M. & Ni, H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 131, 1777–1789 (2018).
5. Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590 (2011).

6. Arita, T., Ichikawa, D., Konishi, H., Komatsu, S., Shiozaki, A., Hiramoto, H. et al. Increase in peritoneal recurrence induced by intraoperative hemorrhage in gastrectomy. Ann. Surg. Oncol. 22, 758–764 (2015).
7. Wang, S., Li, Z. & Xu, R. Human cancer and platelet interaction, a potential therapeutic target. Int. J. Mol. Sci. 19, 1246 (2018).
8. Ito, Y., Kanda, M., Ito, S., Mochizuki, Y., Teramoto, H., Ishigure, K. et al. Intraoperative blood loss is associated with shortened postoperative survival of patients with stage II/III gastric cancer: analysis of a multi-institutional dataset. World J. Surg. 43, 870–877 (2019).
9. Liang, Y. X., Guo, H. H., Deng, J. Y., Wang, B. G., Ding, X. W., Wang, X. N. et al. Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World J. Gastroenterol. 19, 5542–5550 (2013).
10. Kamei, T., Kitayama, J., Yamashita, H. & Nagawa, H. Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer. World J. Surg. 33, 1240–1246 (2009).